Early Phase Leadership Addition Further Strengthens CRO’s Position as a Global Leader in Early Phase Clinical Research

Worldwide Clinical Trials, a global clinical research organization (CRO), has appointed John Capicchioni as Senior Vice President, Commercial, Early Phase. In this role, Capicchioni will lead business development and commercial activities for Worldwide’s Early Phase business unit, which includes the Bioanalytical Center of Excellence in Austin, Texas, and the Clinical Pharmacology Unit in San Antonio, Texas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106838647/en/

John Capicchioni, Senior Vice President, Commercial, Early Phase at Worldwide Clinical Trials

Worldwide’s Early Phase business is driving growth with industry-leading capabilities in first-in-human studies, clinical pharmacology, and bioanalysis for small and large molecules, ensuring seamless support from discovery through clinical phases. Its 200-bed clinical pharmacology unit in San Antonio delivers flexible, customized Phase I studies, while its bioanalytical lab provides cutting-edge technology and rapid turnaround times for PK/PD characterization and supports all bioanalytical needs spanning Phase I-IV. These strengths enable faster, data-driven decisions, positioning Worldwide to provide personalized attention and tailored solutions for early development success.

"We're delighted to welcome John to our team,” said Mike Mencer, Executive Vice President and General Manager, Early Phase. “His extensive industry experience and proven track record of driving sales performance and revenue growth make him an ideal fit for this critical role. We're confident that John's leadership will be instrumental in advancing our Early Phase business and enhancing our position in the market."

Capicchioni brings over 20 years of life sciences business development experience, with a strong record of driving revenue growth, optimizing operations, and leading high-performing teams in global pharmaceutical testing services. Before joining Worldwide, he held senior roles at PPD (Thermo Fisher Scientific), Cliantha Research, and MDS Pharma Services, where he delivered double-digit sales growth and expanded service portfolios and client bases.

“I am thrilled to join Worldwide Clinical Trials and lead Early Phase commercial operations at such a pivotal time for the organization,” said Capicchioni. “Worldwide’s commitment to excellence in bioanalytical and clinical services aligns strongly with my passion for advancing scientific research through strategic leadership and operational precision. I look forward to driving sustainable growth, elevating service delivery, and enhancing client satisfaction as we continue to innovate and expand our capabilities.”

Learn more about Worldwide’s Bioanalytical Services here and Phase I and Clinical Pharmacology Services here.

About Worldwide Clinical Trials:

Worldwide Clinical Trials (Worldwide) is a full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications. Worldwide’s capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies – all powered by an accessible team of clinicians, scientists, and researchers who bring first-hand expertise and a collaborative, personalized approach to each clinical program. Worldwide is therapeutically focused on neuroscience, oncology, rare disease, and cardiometabolic and inflammatory disease. Its global footprint spans over 60 countries with more than 3,500 team members. For more information, visit www.worldwide.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251106838647/en/

His extensive industry experience and proven track record of driving sales performance and revenue growth make him an ideal fit for this critical role. We're confident that John's leadership will be instrumental in advancing our Early Phase business...